Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

Inclusion Criteria: * 1.Diagnosed as multiple myeloma, and has one of the above: 1. high risk karyotype, such as 17p-，t（4；14），t（14；16），t（14；20）或1q gain,1p-, double hit myeloma, triple hit myeloma, etc; 2. RISS-3; 3. IgD/IgE MM; 4. with measurable extra-medullary plasmacytoma; 5. flowcytometry showed peripheral blood plasma cell ≥0.165%； * 2.Secretory MM should have measurable markers, including: 1. specific M protein value (≥5g/L)； 2. and/or involved flc ≥100mg/L； 3. and/or measurable extramedullary foci (diameter\>1cm on CT); * 3.Age≥18 years, male or female; * 4.ECOG 0-2 points, with life expectance ≥3 months; GA score \<2; * 5.ALT/AST level \<2.5 times of the maximum of normal range; total bilirubin\<1.5 times of normal maximum； * 6.Neutrophil count≥1.5×109/L, platelet count≥50×109/L; * 7.eGFR≥40ml/min，except in the case of myeloma-related nephropathy; * 8.Normal left ventricular ejaculation rate, NYHA stage 1, pulmonary function GOLD stage 1; * 9.Willing to accept the possibility of potential adverse events and efficacy observation by the investigators; * 10.Being able to understand and signing the written consent, which should be signed prior to any procedure of the trial. Exclusion Criteria: * 1.With ≥2 degree of peripheral neuropath or with pain; * 2.Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed; * 3.With severe pulmonary/cardiac disfunction (including history of QT interval elongation, ventricular tachycardia, ventricular fibrillation, myocardial infraction) or other severe organ malfunction; * 4.Patients in pregnancy or lactation; * 5.Allergic constitution or being allergic to any drug within the regimen of the trial; * 6.With uncontrolled mental diseases; * 7.With active infection; * 8.With non-myeloma-associated acute renal dysfunction; * 9.With active hepatitis; * 10.HIV positive; * 11.History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma; * 12.With other conditions that the investigators think unfit for the trial.